Belite Bio
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Its last 7 Sell calls were actually followed by a +16% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -2.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 3.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -16.9% | Better than 17% |
| Return on invested capital | -18.4% | Better than 14% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -20.9% | Better than 29% |
| 6-month return | -7.2% | Better than 44% |
| 12-month return (ex latest month) | 24.6% | Better than 64% |
| Distance below 52-week high | 36.3% | Better than 33% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 50.0x | Better than 100% |
| Debt to assets | 0.1% | Better than 99% |
| Interest coverage | -38,804.5x | Better than 0% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 81.9% | Better than 79% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 151.02
- Open
- 129.00
- Day range
- 120.00 - 135.07
- Avg price
- 129.94
- Volume
- 1.04M
- Turnover
- 134.88M
- Turnover ratei
- 5.23%
- Volume ratioi
- 6.95
- Amplitudei
- 9.98%
- 52-week rangei
- 115.41 - 200.00
Valuation
- P/Ei
- -55.14
- P/E (TTM)i
- -44.85
- P/Bi
- 6.71
- EPSi
- -2.31
- Book value / shi
- 18.99
- Net profit
- -93.82M
- Net assets
- 771.06M
Share structure
- Market cap
- 5.17B
- Float capi
- 2.53B
- Shares out
- 40.61M
- Float sharesi
- 19.85M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2022-04-29
36.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-12.67M net over the window
Short interest
- Shares short
- 1.38M
- % of floati
- 3.43%
- Days to coveri
- 9.96
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Belite Bio (BLTE)?
Belite Bio last traded at 127.38. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Belite Bio's market cap?
About 5.17B.
What is the P/E ratio of Belite Bio?
The trailing twelve-month P/E is -44.85. The Valuation tab shows it against the stock's own five-year range.
Does Belite Bio pay a dividend?
Belite Bio does not currently pay a regular dividend.
Is Belite Bio a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 231.67, which implies 81.9% upside from the current price. This is not investment advice.
What is Belite Bio's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Belite Bio a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Belite Bio discussion 0 comments